These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8307059)

  • 1. Multiple sclerosis: new therapeutic concepts or better use of old drugs?
    Clanet M
    Eur Neurol; 1993; 33(6):401-2. PubMed ID: 8307059
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon beta-1b for the treatment of multiple sclerosis.
    Petri T; Weber-Diehl F
    J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
    [No Abstract]   [Full Text] [Related]  

  • 3. [PRISMS Study. Interferon-beta 1a (Rebif) in relapsing multiple sclerosis].
    Hartung HP; Flachenecker P; Weilbach FX; Rieckmann P
    Nervenarzt; 1999 Feb; 70(2):182-5. PubMed ID: 10098156
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon beta in multiple sclerosis.
    Gross M
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465198
    [No Abstract]   [Full Text] [Related]  

  • 5. Interferon beta in multiple sclerosis.
    Napier JC
    Lancet; 1999 Aug; 354(9177):512; author reply 512-3. PubMed ID: 10465197
    [No Abstract]   [Full Text] [Related]  

  • 6. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple sclerosis therapy. A practical guide.
    van Oosten BW; Truyen L; Barkhof F; Polman CH
    Drugs; 1995 Feb; 49(2):200-12. PubMed ID: 7729328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.
    Richert ND; Zierak MC; Bash CN; Lewis BK; McFarland HF; Frank JA
    Mult Scler; 2000 Apr; 6(2):86-90. PubMed ID: 10773853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
    Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon-beta in treatment of relapsing multiple sclerosis].
    Hartung HP; Hohlfeld R
    Nervenarzt; 1994 Feb; 65(2):139-45. PubMed ID: 8164769
    [No Abstract]   [Full Text] [Related]  

  • 11. New tools for biotech product development.
    Quay S
    Biotechnology (N Y); 1995 Apr; 13(4):319-20. PubMed ID: 9678946
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon beta-1b.
    Goodkin DE
    Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
    [No Abstract]   [Full Text] [Related]  

  • 13. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Schmidt S; Hertfelder HJ; von Spiegel T; Hering R; Harzheim M; Lassmann H; Deckert-Schlüter M; Schlegel U
    Neurology; 1999 Jul; 53(1):220-2. PubMed ID: 10408566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon beta-1b in multiple sclerosis--news regarding open questions].
    Nervenarzt; 1997 Aug; 68(8 Suppl Interferon):1-4. PubMed ID: 9380220
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of interferons in demyelinating disease.
    Johnson KP
    J Neural Transm Suppl; 1997; 49():111-5. PubMed ID: 9266420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
    Stone LA; Frank JA; Albert PS; Bash CN; Calabresi PA; Maloni H; McFarland HF
    Neurology; 1997 Sep; 49(3):862-9. PubMed ID: 9305355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1B--hope or hype?
    Drug Ther Bull; 1996 Feb; 34(2):9-11. PubMed ID: 8819985
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple sclerosis.
    Noseworthy JH; Lucchinetti C; Rodriguez M; Weinshenker BG
    N Engl J Med; 2000 Sep; 343(13):938-52. PubMed ID: 11006371
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b.
    Laske C; Oschmann P; Tofighi J; Kühne BS; Diehl H; Bregenzer T; Kraus J; Chatzimanolis N; Bauer R; Traupe H; Kaps M
    Eur Neurol; 2001; 46(4):210-4. PubMed ID: 11721129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.